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641encouraging, they are preliminary and do not have
the strength of evidence to completely redeﬁne risk
reduction behaviors for lymphedema. Prospective
larger studies are needed to address this concern.
Ipsilateral transradial cardiac catheterization can
be safely performed in breast cancer survivors
without increasing the risk of lymphedema or other
vascular arm complications.Pradeep K. Yadav, MD
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of the letter.Coronary In-Stent
Restenosis in Patients
Treated With Thoracic
External Beam Radiation
for CancerWe read with interest the paper of Liang et al. (1)
about the outcomes of percutaneous coronary in-
terventions (PCI) with stents in patients undergoing
external beam thoracic radiation therapy (EBRT) for
cancer. The authors identiﬁed 115 patients treated
with EBRT a median 3.6 years after stenting (group
A) and 45 patients treated with EBRT a median2.2 years before stenting (group B), demonstrating
that long-term mean target lesion revascularization
rates in group A (3.2 vs. 6.6%; hazard ratio: 0.6; 95%
conﬁdence interval: 0.2 to 1.6; p ¼ 0.31) and
group B (9.2 vs. 9.7%; hazard ratio: 1.2; 95% conﬁ-
dence interval: 0.4 to 3.4; p ¼ 0.79) were similar to
rates in corresponding control patients (group A:
1,390 control patients; group B: 439 control pa-
tients). The authors concluded that thoracic EBRT is
not associated with increased stent failure rates
when used before or after PCI, and a history of PCI
should not preclude the use of curative thoracic
EBRT in cancer patients or vice versa. However,
restenosis is a complex process involving multiple
players, especially in patients with cancer. As re-
ported by the authors, the effect of EBRT on vascular
stents remains unclear, as both animal and human
studies have found variable effects of EBRT on pre-
venting stenosis in coronary and noncoronary arteries
after arterial injury and stenting. Moreover, in pa-
tients with cancer the administration of systemic
chemotherapy may also affect the restenotic process.
Of importance, some chemotherapy drugs (i.e.,
paclitaxel for breast cancer and non-small cell lung
cancer, ﬂudarabine for non-Hodgkin lymphoma) are
well-known antiproliferative agents with established
effects on vascular smooth muscle cells and also used
for drug-eluting stent technology to reduce neointima
proliferation (2,3). As a consequence, we think it
would be of interest to consider in the analysis the
effect of concomitant chemotherapy, in order to
clarify the role of thoracic EBRT on PCI outcomes in
patients with cancer.*Rocco A. Montone, MD
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